Oncomark
Dublin
About Oncomark
OncoMark is a UCD spin-out that develops companion diagnostic tests to support cancer drug development. Companion diagnostics allow pharmaceutical companies to select patients for which a drug may be particularly effective (patient stratification). The test can also be used during clinical trials to help reduce the numbers of patients required to complete a clinical trial and its duration, while also increasing the likelihood that the trial will be successful. The end result is improved outcome for cancer patients. The company has a portfolio of diagnostic tests in development, covering some of the key cancer types (breast, colorectal, prostate, melanoma), supported by €3.9m in EU R&D funding. There are currently 12 employees funded through 6 grants. The company was founded by Prof. William Gallagher in UCD and is led by Dr. Mairin Rafferty, the CEO/COO. The company has a strong advisory board, which includes Prof. John Crown and Prof. Bryan Hennessy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $5.3M
- Funding stage: M&A
- Last round: Series Unknown (Nov 2017)
- Website: oncomark.com
- Phone: +353 1 716 3666
Industries & Categories
Biotechnology, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/oncomark-194151 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.